Skip to main content
Fagron N.V. logo

Fagron N.V. — Investor Relations & Filings

Ticker · FAGR ISIN · BE0003874915 LEI · 549300TRKRUFK2RRG779 BR Manufacturing
Open in API
Filings indexed 1,987 across all filing types
Latest filing 2026-01-09 Major Shareholding Noti…
Country BE Belgium
Listing BR FAGR

About Fagron N.V.

https://fagron.com/

Fagron N.V. is a global company active in pharmaceutical compounding, focusing on the delivery of personalized medicine. The company optimizes and innovates compounding to widen the therapeutic options for prescribers worldwide. Fagron develops, markets, and distributes pharmaceutical raw materials, equipment, and specially formulated vehicles and bases, such as the Pentravan® transdermal base and the SyrSpend® range of oral suspending vehicles. Its primary customers are hospitals, pharmacies, and clinics. The company also operates in the field of genomics to further support personalized healthcare solutions.

Recent filings

Filing Released Lang Actions
Openbaarmaking van kennisgeving ontvangen van BNP Paribas.pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal notification regarding a change in major shareholding (crossing the 3% threshold) by BNP Paribas Asset Management Holding in the company Fagron. This type of disclosure is a standard regulatory requirement for listed companies to report significant changes in ownership, which falls under the 'Major Shareholding Notification' category.
2026-01-09 Dutch
Fagron announces the completion of Purifarma
M&A Activity Classification · 100% confidence The document is a press release announcing the completion of an acquisition (Purifarma) by Fagron. It details the strategic rationale, financial impact (enterprise value), and quotes from the CEO. This falls squarely under M&A activity (mergers and acquisitions).
2026-01-06 Dutch
Fagron announces the completion of Purifarma
M&A Activity Classification · 100% confidence The document is a press release announcing the completion of an acquisition (Purifarma) by Fagron. It details the strategic rationale, financial impact (enterprise value), and CEO commentary regarding the transaction. This falls squarely under M&A activity (takeover/acquisition completion).
2026-01-06 English
Fagron announces the completion of Purifarma.pdf
M&A Activity Classification · 100% confidence The document is a press release announcing the completion of an acquisition (Purifarma) by Fagron. It details the strategic rationale, financial impact (enterprise value), and CEO commentary regarding the transaction. This falls squarely under M&A activity (takeover/acquisition completion).
2026-01-06 English
Fagron kondigt de afronding van de overname van Purifarma aan.pdf
M&A Activity Classification · 100% confidence The document is a press release announcing the completion of an acquisition (Purifarma) by Fagron. It details the strategic rationale, financial impact (enterprise value), and quotes from the CEO. This falls squarely under M&A activity (mergers and acquisitions).
2026-01-06 Dutch
Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone
M&A Activity Classification · 95% confidence The document is a press release from Fagron announcing two strategic acquisitions (Amber Compounding Pharmacy and Vepakum) and a regulatory licensing update in North America. It also includes a brief mention of a change in the Board of Directors. While it contains multiple topics, the primary purpose is to announce corporate developments and M&A activity. According to the filing definitions, M&A activity is classified as 'TAR'. Although there is a mention of a board change, the document is primarily an announcement of strategic business expansion.
2025-12-19 Dutch

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.